Amgen Inc.
AMGN
NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $236.0B
$437.23
▼ -1.55%
P/E
27.12
Mkt Cap
$236.0B
52-Wk Range
$269.77–$447.03
52-Week Range
$269.77 - $447.03
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 56.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Extensive portfolio of blockbuster biologics with high barriers to entry and patent protection
- Established manufacturing and distribution infrastructure with direct relationships to healthcare providers
- Strong R&D pipeline with strategic partnerships (Novartis, Eli Lilly, Kyowa Kirin, BeiGene) accelerating drug development
- Recurring revenue from chronic disease treatments serving aging populations with high treatment adherence
- Regulatory expertise and FDA relationships enabling faster approvals for new indications and therapies
Bear Case
2 risks
- Low volatility (beta 0.4).
- Premium valuation to Large Cap Pharma peers
Growth
Stable outlook
Expanding global demand for biologics in aging populations with chronic diseases
Value
Premium valuation to Large Cap Pharma peers
Momentum
Hot
+26.5% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
2.27% yield
Smart-money signal
Who's buying AMGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of $6.29 vs $5.62 consensus (+11.9% surprise). Revenue of $10.1B vs $9.4B expected (+6.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.9%
Revenue trend · last 8Q
—
+11%
+9%
+9%
+12%
+9%
+6%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$8.5B
$9.1B
$8.1B
$9.2B
$9.6B
$9.9B
$8.6B
$10.1B
Margins · last 8Q
Gross
72.0%
Operating
35.0%
Profit
23.6%
Wall Street consensus
13 analysts · 54% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
54%
Hold
46%
Sell
0%
Median Price Target
—
Latest: Wells Fargo · Sep 4, 2026
vs Industry
How AMGN stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related